

TRADE SECRET

Study Title

H-24943: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

Laboratory Project ID: DuPont-6544

AUTHOR: Carol Finlay, B.A.

STUDY COMPLETED ON: November 26, 2001

PERFORMING LABORATORY: E.I. du Pont de Nemours and Company
Haskell Laboratory for Health and Environmental Sciences
Elkton Road, P.O. Box 50
Newark, Delaware 19714-0050

[REDACTED]
[REDACTED]

Company Sanitized. Does not contain TSCA CBI

CERTIFICATION

We, the undersigned, declare that this report provides an accurate evaluation of data obtained from this study.

Reviewed by: *Paul Hinderliter* 26-Nov-2001
Paul Hinderliter, Ph.D. Date
Postdoctoral Fellow

Reviewed by: *Judith C. Stadler* 26-NOV-2001
Judith C. Stadler, Ph.D., D.A.B.T. Date
Director

Issued by Study Director: *Carol Finlay* 26-NOV-2001
Carol Finlay, B.A. Date
Staff Scientist

Company Sanitized. Does not contain TSCA CBI

TABLE OF CONTENTS

	Page
CERTIFICATION	2
LIST OF TABLES	4
LIST OF FIGURES	4
LIST OF APPENDICES	5
STUDY INFORMATION	6
STUDY PERSONNEL	8
SUMMARY	9
INTRODUCTION	11
MATERIALS AND METHODS	11
A. Test Substance and Positive Controls	11
B. Test Species	11
C. Animal Husbandry	11
D. Quarantine and Pretest	12
E. Study Design	13
F. Assignment to Groups and Study Start	13
G. Dosing Material Preparation and Administration	13
H. Body Weights	14
I. Mortality and Clinical Observations	14
J. Collection and Analysis of Blood, Livers, and Fat	14
K. Treatment of Fluorine Data	15
L. Statistical Methods	15
RESULTS AND DISCUSSION	16
A. In-Life Toxicology	16
B. Liver Weights	16
C. Fluorine Data	17
CONCLUSIONS	18
RECORDS AND SAMPLE STORAGE	19
TABLES	20
FIGURES	27
APPENDICES	38

Company Sanitized. Does not contain TSCA CBI

LIST OF TABLES

	Page
1. MEAN BODY WEIGHTS.....	21
2. MEAN BODY WEIGHT GAINS.....	22
3. MEAN BODY AND LIVER WEIGHTS.....	23
4. MEAN BLOOD FLUORINE LEVELS.....	24
5. MEAN BLOOD FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	24
6. MEAN LIVER FLUORINE LEVELS.....	25
7. MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	25
8. MEAN FAT FLUORINE LEVELS.....	26
9. MEAN FAT FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	26

LIST OF FIGURES

	Page
1. MEAN BODY WEIGHTS.....	28
2. COMPARISON OF MEAN RELATIVE LIVER WEIGHTS: TEST SUBSTANCE AND NEGATIVE CONTROL.....	29
3. COMPARISON OF MEAN RELATIVE LIVER WEIGHTS: TEST SUBSTANCE AND POSITIVE CONTROLS.....	30
4. MICROMOLAR EQUIVALENTS IN RAT BLOOD.....	31
5. NORMALIZED H-24943 AND POSITIVE CONTROL BLOOD AUCINFD RESULTING FROM A 10-DAY ORAL GAVAGE.....	33
6. MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	34
7. COMPARISON OF RELATIVE LIVER WEIGHT AND MEAN LIVER FLUORINE CONCENTRATION FOR H-24943 AND NEGATIVE CONTROL.....	35
8. MEAN FAT FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	36
9. COMPARISON OF MEAN BLOOD, MEAN LIVER, AND MEAN FAT FLUORINE CONCENTRATION NORMALIZED TO DOSE.....	37

Company Sanitized. Does not contain TSCA CB1

LIST OF APPENDICES

	Page
A. INDIVIDUAL BODY WEIGHTS	39
B. INDIVIDUAL CLINICAL OBSERVATIONS.....	49
C. TERMS AND CALCULATIONS FACTORS INFLUENCING INTERPRETATION OF KINETIC ANALYSIS	65
D. INDIVIDUAL FLUORINE LEVELS IN BLOOD	69
E. INDIVIDUAL FLUORINE LEVELS IN LIVER	76
F. INDIVIDUAL FLUORINE LEVELS IN FAT	80

STUDY INFORMATION

TEST SUBSTANCE:

Substance Tested: [REDACTED]

Synonyms/Codes: [REDACTED]

H-24943

Haskell Number: 24943

Composition: [REDACTED]

Known Impurities: [REDACTED]

POSITIVE CONTROL:

Substance Tested: Potassium perfluoroalkyl sulfonate

Synonyms/Codes: • H-24019

• PFOS

Haskell Number: 24019

Composition: [REDACTED]

Known Impurities: Unknown

Company Sanitized. Does not contain TSCA CBI

STUDY INFORMATION (Continued)

POSITIVE CONTROL:

Substance Tested: Octanoic acid, pentadecafluoro-, ammonium salt

Synonyms/Codes: • H-24020

- [REDACTED]
- C-8
 - Perfluorooctanoate, ammonium salt
 - APFO
 - Ammonium perfluorooctanoate

Haskell Number: 24020

Composition: [REDACTED]

Known Impurities: [REDACTED]

Sponsor: E. I. du Pont de Nemours and Company
Wilmington, Delaware 19898
U.S.A.

Study Initiated/Completed: May 22, 2001 / (see report cover page)

In-Life Initiated/Completed: May 22, 2001 / August 23, 2001

Company Sanitized. Does not contain TSCA CBI

STUDY PERSONNEL

Study Director: Carol Finlay, B.A.
Management: Judith C. Stadler, Ph.D., D.A.B.T.
Primary Technician: James C. Mackay II

Fluorine Data Analysis: Paul M. Hinderliter, Ph.D.
Management: Matthew S. Bogdanffy, Ph.D., D.A.B.T.

Toxicology Report Preparation: Wanda F. Dinbokowitz

Laboratory Veterinarian: William Singleton, D.V.M., A.C.L.A.M

Company Sanitized. Does not contain TSCA CBI

SUMMARY

The objective of this study was to evaluate the potential for H-24943, when administered by gavage, to be absorbed and to accumulate in a mammalian system. Two groups of 5 male Crl:CD®(SD)IGS BR rats each were exposed to 1000 mg/kg/day of H-24943 for 10 consecutive days. Blood was collected from the orbital sinus of 5 rats (group I) approximately 2 hours after dosing on test days 1 and 5. Approximately 2 hours after the last dose, these rats were euthanized and blood, livers, and fat were collected. Blood was collected from the orbital sinus of the remaining 5 rats (group III) on test days 13, 24, and 52. These rats were euthanized on test day 94 and blood, livers, and fat were collected. Body weights and clinical signs were recorded on each day of dosing and then weekly during the recovery period. Additionally, a negative control, deionized water, and 2 positive controls, H-24019 (10 mg/kg/day) and H-24020 (20 mg/kg/day), were tested as described for H-24943.

No deaths occurred. One rat dosed with the test substance exhibited black nasal discharge during the dosing period.

Comparison of body weights was complicated by the fact that there was a difference in age on test day 1 between the rats dosed with the test substance and those dosed with the positive controls or negative control. This difference resulted in differences in mean body weights on test day 1. Accounting for the age difference at study start and the expected rate of body weight gain, the mean body weights and mean body weight gains of the rats dosed with H-24943 were comparable to the weights of the positive and negative control rats.

The mean relative liver weights (liver/body weight) of rats dosed with the test substance, H-24943, were similar to the weights of the negative control rats on day 10 and day 94. The mean relative liver weight of rats dosed with the positive control H-24019 was 38% higher at day 10 than the negative control group. The mean relative liver weight of rats dosed with the positive control H-24020 was 88% higher on day 10 than the negative control group. By day 94, the mean relative liver weights of rats dosed with H-24019 and H-24020 were similar to the negative control group.

A steady-state for fluorine levels in whole blood was not achieved during 10 consecutive days of dosing with 1000 mg/kg H-24943. An area under the curve (estimated to infinity) was calculated and normalized for fluorine content for the test substance and each positive control. The AUCINF/D for the fluorine component of the test substance, H-24943, was 1.62×10^3 compared to AUCINF/D values of 5.22×10^5 and 8.15×10^4 for H-24019 and H-24020, respectively.

The concentration of fluorine in the livers from rats dosed with the test substance, H-24943, was 47.7 μ M equivalents on day 10 and 2.9 μ M equivalents on day 94. On day 10, mean μ M equivalent concentrations of fluorine in the livers from rats dosed with the positive control materials were approximately 100-fold (H-24019) and 18-fold (H-24020) greater than the fluorine concentration in livers from rats treated with the test substance. By day 94, the

Company Sanitized. Does not contain TSCA CBI

concentrations were approximately 450x and 6x the fluorine concentration in rats treated with H-24943.

The fluorine concentration in the fat from rats dosed with the test substance was 41.3 μM equivalents on day 10. On day 94, the concentration was 6.6 μM equivalents. The fluorine concentration of the positive control H-24019 was approximately 5x higher than H-24943 on day 10. By day 94, the μM equivalent concentration of fluorine in the fat from rats dosed with the positive control H-24019 was approximately 2x higher than H-24943. The fluorine concentration of the positive control H-24020 was slightly higher on day 10 than the concentration in fat from rats dosed with the test substance. There was no detectable fluorine by day 94 in the fat from rats dosed with H-24020.

The μM equivalents of fluorine in the liver and fat of animals dosed with the test substance were higher than levels in the blood.

Under the conditions of this study, there was limited absorption and no retention of fluorine in the blood in rats dosed with H-24943. Administration of the test substance, H-24943, to male rats for 10 consecutive days resulted in some absorption and retention of fluorine in the liver; however, there was no evidence of increased relative liver weight, either at the end of dosing or following the recovery period. Fluorine levels in blood and liver in rats dosed with H-24943 were lower than the levels in rats dosed with the positive control materials, H-24019 and H-24020. Some retention of fluorine in the fat was evident. Fluorine levels in the fat from rats dosed with the test substance were lower than the levels in fat from rats dosed with the positive control H-24019 and were slightly lower on day 10 than the levels in fat from rats dosed with the positive control H-24020, but higher on day 94.

Company Sanitized. Does not contain TSCA CBI

INTRODUCTION

The objective of this study was to define the potential of H-24943 to be absorbed and to bioaccumulate in a mammalian system, as indicated by analytical determination of total fluorine in blood, liver, and fat. The test substance was compared to 2 positive controls that were materials previously shown to bioaccumulate in mammals.

The daily dosage of 1000 mg/kg for the test substance was selected based on available toxicity data. The dosage of 1000 mg/kg was selected for the limit dosage for this project. The limit dosage of 1000 mg/kg was chosen for the study and was expected to produce less than a 10% difference in mean body weight over 10 days when compared to the negative control.

MATERIALS AND METHODS

A. Test Substance and Positive Controls

The test substance, H-24943, was supplied by the sponsor as a cloudy yellow-amber liquid. The positive controls, H-24019 and H-24020, were supplied by the sponsor as white solids. The test substance and positive controls appeared to be stable under the conditions of the study. No evidence of instability, such as a change in color or physical state, was observed.

B. Test Species

Male CrI:CD[®](SD)IGS BR rats were received from Charles River Laboratories, Inc., Raleigh, North Carolina. The CrI:CD[®](SD)IGS BR rat was selected on the basis of extensive experience with this strain and its suitability with respect to longevity, hardiness, sensitivity, and low incidence of spontaneous diseases.

C. Animal Husbandry

1. Housing Environment

Rats were housed singly in stainless steel, wire-mesh cages suspended above cage boards. Animal rooms were maintained on an approximate 12-hour light/dark cycle (fluorescent light) and at a temperature of $23 \pm 1^{\circ}\text{C}$ and a relative humidity of $50 \pm 10\%$.

2. Feed and Water

Tap water was provided *ad libitum*. All rats were fed PMI Nutrition International, Inc. Certified Rodent LabDiet[®] 5002 chow. The feed is guaranteed by the manufacturer to meet specified nutritional requirements and to be free of specified contaminants.

Company Sanitized. Does not contain TSCA CBI

3. Identification

Each rat was assigned a unique identification number which was recorded on a card affixed to the cage. The last 3 digits of the number were tattooed on the tail of each rat.

4. Animal Health Monitoring Program

As specified in the Haskell Laboratory animal health and environmental monitoring program, the following procedures are performed periodically to ensure that contaminant levels are below those that would be expected to impact the scientific integrity of the study:

- Water samples are analyzed for total bacterial counts, and the presence of coliforms, lead, and other contaminants.
- Feed samples are analyzed for total bacterial, spore and fungal counts.
- Samples from freshly washed cages and cage racks are analyzed to ensure adequate sanitation by the cagewashers.

Certified animal feed is used, guaranteed by the manufacturer to meet specified nutritional requirements and not to exceed stated maximum concentrations of key contaminants, including specified heavy metals, aflatoxin, chlorinated hydrocarbons, and organophosphates. The presence of these contaminants below the maximum concentration stated by the manufacturer would not be expected to impact the integrity of the study.

The animal health and environmental monitoring program is administered by the attending laboratory animal veterinarian. Evaluation of these data did not indicate any conditions that affected the validity of the study.

D. Quarantine and Pretest

Upon arrival at Haskell Laboratory, the rats were removed from shipping cartons and quarantined for 6 days. The rats were weighed 3 times during the pretest period and examined daily for any clinically apparent signs of disease or injury. The rats were observed daily for mortality and signs of illness, injury, or abnormal behavior.

On the bases of acceptable body weight gains and freedom from clinically apparent signs of disease or injury, the rats were released from quarantine by the designee of the laboratory animal veterinarian.

E. Study Design

Substance	Vehicle	Dosage (mg/kg)	Number of Animals
Negative Control Deionized water	Not applicable	0	10
Positive Controls H-24019	Acetone/Corn Oil	10	10
H-24020	Acetone/Corn Oil	20	10
Test Substance H-24943	Not applicable	1000	10

F. Assignment to Groups and Study Start

After the quarantine period, the rats were selected on the bases of adequate body weight gain and freedom from any clinical signs of disease or injury. The selected rats were arbitrarily assigned to each group.

After assignment to groups, each rat was housed individually. The rats were 7 or 8 weeks of age at the time of dosing. Dosing began on test day 1.

Rats that were not assigned to the study were released for other laboratory purposes, or were sacrificed by carbon dioxide asphyxiation and discarded without pathology evaluation.

G. Dosing Material Preparation and Administration

1. Test Substance

H-24943 was dosed as received. The amount of test substance each rat received was based on the body weight collected on each day of dosing and the test substance density of 1.06 g/mL. The test substance was stirred on a magnetic stir plate throughout the dosing procedure to maintain homogeneity.

2. Positive Controls

It was necessary to dissolve H-24019 and H-24020 in acetone before suspending them in corn oil. The ratio of acetone to corn oil was 20:80. The amount each rat received was based on the body weight collected on each day of dosing and the suspension concentration. The rats were dosed at a volume of 1 mL/100 g of body weight. The dosing preparations were stirred on a magnetic stir plate throughout the dosing procedure to maintain homogeneity.

3. Negative Control

Deionized water was chosen as the negative control. The rats were dosed at a volume of 1 mL/100 g of body weight. These rats were dosed in a separate room from the rats dosed with the test substance or positive controls.

Company Sanitized. Does not contain TSCA CBI

H. Body Weights

All rats were weighed on each day of dosing and weekly during the recovery period.

I. Mortality and Clinical Observations

Cage-site examinations to detect moribund or dead rats and abnormal behavior and appearance among rats were conducted at least once daily throughout the study. At every weighing, each rat was individually handled and examined for abnormal behavior and appearance.

J. Collection and Analysis of Blood, Livers, and Fat

At time points selected for blood sampling other than sacrifice days, approximately 1 mL of blood was collected into EDTA tubes from the orbital sinus of each rat. Rats designated for sacrifice were euthanized by carbon dioxide anesthesia and exsanguination and blood, livers, and fat were collected according to the following schedules:

Group	Dosing Days	Tissue Collected	Sampling Time
I	1-10	Blood	Test day 1 (2 hours post dosing)
I	1-10	Blood	Test day 5 (2 hours post dosing)
I	1-10	Blood, Liver, and Fat	Test day 10 at sacrifice (2 hours post dosing)
III	1-10	Blood	Test day 13
III	1-10	Blood	Test day 24
III	1-10	Blood	Test day 52
III	1-10	Blood, Liver, and Fat	Test day 94

As much blood as possible was collected into EDTA tubes at sacrifice. The livers and fat were weighed. The fat weights were used only for the calculation of fluorine levels. The liver weights were used for the calculation of fluorine levels and for the calculation of liver weight relative to total body weight. The blood from all rats was refrigerated and the livers were frozen. The livers and fat were appropriately packaged and shipped refrigerated to Jackson Laboratory, Deepwater, New Jersey where they were analyzed for total fluorine. The liver and fat samples remained frozen while shipped.

The total fluorine content of the samples was determined by using a Wickbold torch combustion method, followed by analysis with a fluoride ion selective electrode. The samples were decomposed or volatilized in the presence of wet oxygen and swept through an oxy-hydrogen flame in a closed quartz apparatus. The combustion products were collected in an aqueous absorbing solution and analyzed with a fluoride ion selective electrode. Kinetic analysis of the data received (ppm F in each sample) was performed by Haskell Laboratory personnel for evaluation of fluorine biopersistence.

Company Sanitized. Does not contain TSCA CBI

K. Treatment of Fluorine Data

Since the test substance and positive control materials had different toxicity profiles, it was not possible to administer a uniform mg/kg dose for all test materials. Properly conducted kinetic comparisons in situations with varied doses required the use of a normalized dose. The dose-normalization was conducted in μ molar units to accommodate test material molecular weight differences and was adjusted to an arbitrary normalized dose of 0.1 mmoles/kg.

H-24019 and H-24020 were used as positive controls and a dosing diluent was used as the negative control. The percent of fluorine and molecular weight of the test substance and positive controls were used as provided by the sponsor. The measured total fluorine values were used as received (ppm F) from Jackson Laboratory. For the Wickbold torch method, the background fluorine level is 0.2 ppm. This is the limit of detection (LOD) of this method and was subtracted from each sample. The limit of quantification (LOQ) for this method is 0.5 ppm, and any values listed as less than 0.5 ppm were excluded from further treatment.

Since the dosages and molecular weight for positive controls and test material differed, the data were converted from a mass to a molar basis. In addition, the data were standardized to a single reference dose to allow comparison between compounds of differing fluorine content. The doses were first converted from a mg of test material basis to millimoles of fluorine. Raw fluoride ion data (ppm F) were then normalized to a 0.1 millimole dose of active component. Finally the molar dosage and normalized concentration were combined to yield the μ molar (μ M) equivalents of active component in the tissue. Detailed calculations can be found in Appendix C. The μ M equivalents can be compared across compounds provided the considerations listed in Appendix C are observed.

Noncompartmental analysis was conducted on fluorine data derived from rats dosed with H-24943 and the positive controls using WinNonlin Version 3.1 software (Pharsight Corp, Mountain View, CA). WinNonlin software provided a means of computing derived pharmacokinetic parameters from experimental data. All analysis was calculated using the μ M equivalent in the data.

The maximum observed concentration in blood was C_{max} (μ M equivalent). Biopersistence was assessed by quantifying terminal elimination blood half-life ($T_{1/2}$, days). The points included in determination of the $T_{1/2}$ were selected manually and included only points after apparent log-linear elimination was achieved. Internal exposure was determined by calculating the blood area-under-the-curve (AUC). AUC, which is simply the integral of blood concentration over time, is the most common means for expressing internal dose. With the calculated half-life, the AUC can be extrapolated to infinity (AUCINF) to reflect the elimination of the compound. AUCINF normalized to dose (AUCINF/D) can be used to compare the relative exposures of different compounds and dosages.

L. Statistical Methods

Descriptive statistics (e.g. mean, standard deviation) were used.

Company Sanitized. Does not contain TSCA CBI

RESULTS AND DISCUSSION

A. In-Life Toxicology

(Tables 1-2, Figure 1, Appendices A-B)

No deaths occurred. Black nasal discharge was observed during the dosing period in a rat dosed with the test substance. Hair loss observed in 2 rats dosed with the test substance was considered spurious. A swollen mouth was observed during the dosing period in a negative control rat. One negative control rat exhibited black nasal discharge during the recovery period. Hair loss was observed in rats dosed with H-24019 and H-24020, and a wound was observed in a rat dosed with H-24020. Ocular discharge, dark eyes, corneal opacity, enophthalmus, and exophthalmus observed in several rats are considered to be a result of orbital sinus bleeding.

Comparison of body weights was complicated by the fact that there was a difference in age on test day 1 between the rats dosed with the test substance and those dosed with the positive controls or negative control. This difference resulted in differences in mean body weights on test day 1. The rats dosed with the test substance, H-24943, were older and heavier in weight than the positive and negative control rats. Accounting for the age difference at study start and the expected rate of body weight gain, the mean body weights and mean body weight gains of the rats dosed with H-24943 were comparable to the positive and negative control.

B. Liver Weights

(Table 3, Figures 2, 3, and 7)

1. Test Substance

The mean relative liver weights (liver/body weight) of rats dosed with the test substance, H-24943, were similar to the weights of the negative control rats on day 10 and day 94.

2. Positive Controls

The mean relative liver weight of rats dosed with one of the positive controls, H-24019, was 32% higher at day 10 than the liver weight of rats dosed with the test substance, H-24943. By day 94, the weights were similar.

The mean relative liver weight of rats dosed with the other positive control, H-24020, was 80% higher at day 10 than the liver weight of rats dosed with H-24943. By day 94, the weights were similar.

The mean relative liver weight of rats dosed with H-24019 was 38% higher at day 10 than the negative control group. By day 94, the mean relative liver weight of rats dosed with H-24019 was similar to the negative control group. The mean relative liver weight of rats dosed with

Company Sanitized. Does not contain TSCA CBI

H-24020 was 88% higher on day 10 than the negative control group. By day 94, the weights were similar.

Therefore, liver weights of rats dosed with the test substance, H-24943, were not affected.

C. Fluorine Data

(Tables 4-9, Figures 4-9, Appendices C-F)

1. Factors Influencing Interpretation of Analysis

The data used in the kinetic analysis were derived from a limited screen, and therefore several caveats and considerations are important. A couple of considerations of particular importance are (1) a single dosage was used and kinetics may or may not be linear, (2) the kinetics apply only to blood, (3) steady-state may not have been achieved, and (4) the sample size is low and may impact calculation of the terminal half-life. A more complete list of considerations is shown in Appendix C.

2. Positive Controls

The positive controls were H-24019 and H-24020. The H-24019 and H-24020 normalized μM equivalents in rat blood continued to rise throughout the dosing period and may not have reached steady-state (Figures 4A and 4B). The C_{max} for H-24019 was $541.45 \pm 50.37 \mu\text{M}$ equivalents (Mean $\pm$ SD) with a terminal half-life of 42.2 days. The C_{max} for H-24020 was $1043.08 \pm 54.57 \mu\text{M}$ equivalents (Mean $\pm$ SD) with a terminal half-life of 15.1 days. For each of the positive controls, blood was sampled at seven time points throughout the study, with only four of them occurring post-dose. The small sample size and analytical variability should be taken into account when using the derived terminal half-life for comparative purposes. The total internal exposure resulting from a normalized dose was described by AUCINF/D and was the basis for comparison between positive controls and the test substance. The AUCINF/D for the fluorine component was 5.22×10^5 for H-24019 and 8.15×10^4 for H-24020.

The concentrations of fluorine in the livers on day 10 from rats dosed with the positive control materials were 4802.15 and 866.67 μM equivalents for H-24019 and H-24020, respectively. By day 94, the concentrations were 1292.92 and 17.10 μM equivalents.

The concentrations of fluorine in the fat on day 10 from rats dosed with the positive control materials were 194.46 and 57.25 μM equivalents for H-24019 and H-24020, respectively. By day 94, the concentration of fluorine in the fat from rats dosed with H-24019 was 15.38 μM equivalents. There was no detectable fluorine by day 94 in the fat from rats dosed with H-24020.

3. Test Substance

The H-24943 normalized μM equivalents in rat blood rose rapidly and did not reach steady-state (Figure 4C). The C_{max} for H-24943 was $4.65 \pm 1.49 \mu\text{M}$ equivalents (Mean $\pm$ SD) with a terminal half-life of 19.7 days. Blood was sampled at seven time points throughout the study, with only four of them occurring post-dose. The small sample size and analytical variability

should be taken into account when using the derived terminal half-life for comparative purposes. Since the day 24 and 94 values were below the limit of quantification, only two points were used in the half-life calculation. The total internal exposure resulting from a normalized dose was described by AUCINF/D and was the basis for comparison between H-24943 and the positive controls. The AUCINF/D for the fluorine component of H-24943 was 1.62×10^3 as compared to AUCINF/D values of 5.22×10^5 and 8.15×10^4 for H-24019 and H-24020, respectively.

Levels of total fluorine in livers from rats dosed with the test substance, H-24943, were lower than the levels in livers from rats dosed with the positive control materials. The total fluorine concentration in the liver from rats dosed with H-24943 was 47.7 μM equivalents at day 10 and 2.9 μM equivalents at day 94. For the positive control H-24019, the liver concentrations were approximately 100x higher (day 10) and approximately 450x higher (end of study) than H-24943. For H-24020, the liver concentrations were approximately 18x higher (end of dosing) and 6x higher (end of study) than H-24943.

Levels of total fluorine in fat from rats dosed with the test substance were lower than the levels in fat from rats dosed with the positive control H-24019. Fluorine levels in the fat from rats dosed with the test substance were slightly lower on day 10 than the levels in fat from rats dosed with the positive control H-24020 but higher on day 94. The fluorine concentration in the fat from rats dosed with the test substance was 41.3 μM equivalents on day 10 and 6.6 μM equivalents on day 94. The fluorine concentration in the fat from rats dosed with the positive control H-24019 was approximately 5x higher than H-24943 at day 10 and 2x higher on day 94. The fluorine concentration on day 10 in the fat from rats dosed with the test substance was slightly lower than the concentration in fat from rats dosed with the other positive control, H-24020. By day 94, there was no detectable fluorine the fat from rats dosed with H-24020.

The μM equivalents of fluorine in the liver and fat of animals dosed with the test substance were higher than levels in the blood.

CONCLUSIONS

Rats dosed for 10 consecutive days with 1000 mg/kg H-24943 exhibited no mortality, body weight effects, or liver weight effects. One rat dosed with the test substance exhibited a clinical sign. A steady-state for fluorine in the blood was not achieved during the 10-day dosing period with the test substance. Dose-adjusted areas under the curve (AUCINF/D) for positive controls, H-24019 and H-24020, were approximately 320x and 50x the AUCINF/D for the test substance.

Under the conditions of this study, there was limited absorption and no retention of fluorine in the blood following dosing with H-24943. Administration of the test substance, H-24943, to male rats for 10 consecutive days resulted in some absorption and retention of fluorine in the liver; however, there was no evidence of increased relative liver weight, either at the end of dosing or following the recovery period. Fluorine levels in blood and liver in rats dosed with H-24943 were lower than the levels in rats dosed with the positive control materials, H-24019 and H-24020. Some retention of fluorine in the fat was evident. Fluorine levels in the fat from

Company Sanitized. Does not contain TSCA CBI

rats dosed with the test substance were lower than the levels in fat from rats dosed with the positive control H-24019 and were slightly lower on day 10 than the levels in fat from rats dosed with the positive control H-24020, but higher on day 94.

RECORDS AND SAMPLE STORAGE

All original records will be retained at Haskell Laboratory, E. I. du Pont de Nemours and Company, Newark, Delaware or at Iron Mountain Records Management, 200 Todds Lane, Wilmington, Delaware.

Company Sanitized. Does not contain TSCA CBI

TABLES

Company Sanitized. Does not contain TSCA CBI

TABLE 1
MEAN BODY WEIGHTS (g)

Test Days	<u>Negative Control</u>	<u>Positive Controls</u>		<u>Test Substance</u>
	Deionized Water	H-24019	H-24020	H-24943
1	189.6	184.4	184.1	254.5
2	195.5	189.2	187.8	259.6
3	204.6	199.5	197.8	269.6
4	211.7	206.4	204.8	276.1
5	222.1	216.2	212.5	285.4
6	225.0	222.0	216.0	293.1
7	235.2	229.4	223.6	299.3
8	242.3	233.7	226.9	302.5
9	248.3	240.4	234.2	310.1
10	257.0	246.5	243.0	316.5
17	293.3	290.1	297.4	363.8
24	325.5	313.3	338.6	392.1
31	359.3	348.4	381.9	420.3
38	380.9	370.8	404.9	442.6
45	407.4	403.2	434.4	469.4
52	420.5	422.8	460.6	495.9
59	436.4	439.6	483.1	504.2
66	-	-	-	521.0
67	452.8	455.6	502.7	-
73	472.6	480.1	525.6	528.1
80	489.6	496.5	542.1	546.8
87	497.7	512.2	546.2	566.7
94	511.7	524.6	570.5	580.4

- Indicates the animals were not weighed.

Company Sanitized. Does not contain TSCA CB₁

TABLE 2
MEAN BODY WEIGHT GAINS (g)

Dosing

Test Days	<u>Negative Control</u>	<u>Positive Controls</u>		<u>Test Substance</u>
	Deionized Water	H-24019	H-24020	H-24943
1-5	32.5	31.8	28.4	30.9
5-10	34.9	30.3	30.5	31.1
1-10	67.4	62.1	58.9	62.0

Recovery

Test Days	<u>Negative Control</u>	<u>Positive Controls</u>		<u>Test Substance</u>
	Deionized Water	H-24019	H-24020	H-24943
10-17	36.3	43.6	54.4	47.3
17-24	32.2	23.2	41.2	28.3
24-52	95.0	109.5	122.0	103.8
52-94	91.2	101.8	109.9	84.5
10-94	254.7	278.1	327.5	263.9

Company Sanitized. Does not contain TSCA CBI

TABLE 3
MEAN BODY AND LIVER WEIGHTS (g)
DEIONIZED WATER (NEGATIVE CONTROL)

Test Days	Absolute		Mean Relative
	Body Weight	Liver Weight	Liver Weight (Liver/Body Weight)
10	258.8	10.814	0.042
94	511.7	17.868	0.035

H-24019 (POSITIVE CONTROL)

Test Days	Absolute		Mean Relative
	Body Weight	Liver Weight	Liver Weight (Liver/Body Weight)
10	243.9	14.205	0.058
94	524.6	19.296	0.037

H-24020 (POSITIVE CONTROL)

Test Days	Absolute		Mean Relative
	Body Weight	Liver Weight	Liver Weight (Liver/Body Weight)
10	243.1	19.174	0.079
94	570.5	19.590	0.034

H-24943 (TEST SUBSTANCE)

Test Days	Absolute		Mean Relative
	Body Weight	Liver Weight	Liver Weight (Liver/Body Weight)
10	306.3	13.394	0.044
94	580.4	19.512	0.034

Company Sanitized. Does not contain TSCA CBI

TABLE 4
MEAN BLOOD FLUORINE LEVELS

Test Days	Negative Control	Positive Controls		Test Substance
	Deionized Water (ppm)	H-24019 (ppm)	H-24020 (ppm)	H-24943 (ppm)
1	0.60 ^a	2.60 (0.1) ^b	9.40 (2.4)	1.1 (0.6)
5	- ^c	31.32 (1.1)	74.92 (7.0)	2.2 (0.4)
10	1.10 ^a	68.00 (3.5)	61.76 (5.5)	2.4 (0.7)
13	- ^c	53.98 (1.2)	29.52 (4.9)	1.8 (0.1)
24	0.5 ^a	39.62 (3.4)	11.18 (2.9)	- ^c
52	- ^c	23.56 (2.1)	2.26 (1.1)	0.7 ^d (0.1)
94	- ^c	12.60 (1.2)	0.85 ^d (0.1)	- ^c

- a One of 5 values. Four of the values were below the limit of quantification (LOQ) or non-detectable.
b Standard deviation is in parentheses.
c All values were below the LOQ or non-detectable.
d Mean of 2 of the 5 values. Three of the values were below the LOQ.

TABLE 5
MEAN BLOOD FLUORINE CONCENTRATION NORMALIZED TO DOSE

Test Days	Positive Controls		Test Substance
	H-24019 µM F Equivalents	H-24020 µM F Equivalents	H-24943 µM F Equivalents
1	36.92 (1.1) ^a	66.67 (17.5)	2.0 (1.3)
5	478.77 (17.6)	541.45 (50.4)	4.3 (0.8)
10	1043.08 (54.6)	446.09 (39.7)	4.6 (1.5)
13	827.38 (19.0)	212.46 (35.6)	3.4 (0.2)
24	606.46 (53.1)	79.57 (20.8)	- ^c
52	359.38 (32.7)	14.93 (7.7)	1.0 ^b (0.2)
94	190.77 (19.2)	4.71 ^b (0.5)	- ^c

- a Standard deviation is in parentheses.
b Mean of 2 of the 5 values. Three of the values were below the limit of quantification (LOQ).
c All values were below the LOQ.

Company Sanitized. Does not contain TSCA CBI

TABLE 6

MEAN LIVER FLUORINE LEVELS

Test Days	<u>Negative Control</u>	<u>Positive Controls</u>		<u>Test Substance</u>
	Deionized Water (ppm)	H-24019 (ppm)	H-24020 (ppm)	H-24943 (ppm)
10	0.90 (0.2) ^a	312.34 (19.7)	119.80 (3.5)	22.4 (3.4)
94	0.78 (0.0)	84.24 (7.4)	2.56 (1.3)	1.6 (0.2)

a Standard deviation is in parentheses.

TABLE 7

MEAN LIVER FLUORINE CONCENTRATION
NORMALIZED TO DOSE

Test Days	<u>Positive Controls</u>		<u>Test Substance</u>
	H-24019 μM Equivalents	H-24020 μM Equivalents	H-24943 μM Equivalents
10	4802.15 (303.8) ^a	866.67 (25.5)	47.7 (7.2)
94	1292.92 (114.1)	17.10 (9.8)	2.9 (0.4)

a Standard deviation is in parentheses.

Company Sanitized. Does not contain TSCA CAS

TABLE 8
MEAN FAT FLUORINE LEVELS

Test Days	<u>Negative Control</u> Deionized	<u>Positive Controls</u>		<u>Test Substance</u>
	Water (ppm)	H-24019 (ppm)	H-24020 (ppm)	H-24943 (ppm)
10	- ^a	12.84 (1.7) ^b	8.10 (1.1)	19.4 (5.3)
94	- ^a	1.20 (0.3)	- ^a	3.3 (0.9)

- a All values were below the limit of quantification (LOQ) or non-detectable.
b Standard deviation is in parentheses.

TABLE 9
MEAN FAT FLUORINE CONCENTRATION
NORMALIZED TO DOSE

Test Days	<u>Positive Controls</u>		<u>Test Substance</u>
	H-24019 μM Equivalents	H-24020 μM Equivalents	H-24943 μM Equivalents
10	194.46 (26.8) ^a	57.25 (7.8)	41.3 (11.3)
94	15.38 (4.1)	- ^b	6.6 (1.9)

- a Standard deviation is in parentheses.
b All values were non-detectable.


Company Sanitized. Does not contain TSCA CBI

FIGURES

Company Sanitized. Does not contain TSCA CBI

FIGURE 1

MEAN BODY WEIGHTS (g)



Company Sanitized. Does not contain TSCA CBI

FIGURE 2

COMPARISON OF MEAN RELATIVE LIVER WEIGHTS:
TEST SUBSTANCE AND NEGATIVE CONTROL




FIGURE 3

COMPARISON OF MEAN RELATIVE LIVER WEIGHTS:
TEST SUBSTANCE AND POSITIVE CONTROLS





FIGURE 4


MICROMOLAR EQUIVALENTS IN RAT BLOOD

A. Normalized Rat Blood H-24019 μM Equivalents Resulting from a 10-Day Oral Gavage



Micromolar (μM) equivalents of H-24019 (positive control) in rat blood resulting from a 10-day oral gavage exposure. Values are means and error bars are standard deviation.


B. Normalized Rat Blood H-24020 μM Equivalents Resulting from a 10-Day Oral Gavage



Micromolar (μM) equivalents of H-24020 (positive control) in rat blood resulting from a 10-day oral gavage exposure. Values are means and error bars are standard deviation.

Company Sanitized. Does not contain TSCA CB1

C. Normalized Rat Blood H-24943 μM Equivalents Resulting from a 10-Day Oral Gavage



Micromolar (μM) equivalents of H-24943 (test substance) in rat blood resulting from a 10-day oral gavage exposure. Values are means and error bars are standard deviation.

Company Sanitized. Does not contain TSCA CBI

FIGURE 5

NORMALIZED H-24943 AND POSITIVE CONTROL BLOOD AUCINF/D
RESULTING FROM A 10-DAY ORAL GAVAGE




FIGURE 6

MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE




FIGURE 7

COMPARISON OF RELATIVE LIVER WEIGHT AND MEAN LIVER FLUORINE CONCENTRATION
FOR H-24943 AND NEGATIVE CONTROL




FIGURE 8

MEAN FAT FLUORINE CONCENTRATION NORMALIZED TO DOSE





FIGURE 9

COMPARISON OF MEAN BLOOD, MEAN LIVER, AND MEAN FAT FLUORINE
CONCENTRATION NORMALIZED TO DOSE



APPENDICES

Company Sanitized. Does not contain TSCA CBI

APPENDIX A

Individual Body Weights

Company Sanitized. Does not contain TSCA CBI

INDIVIDUAL BODY WEIGHTS

EXPLANATORY NOTES

ABBREVIATIONS:

FD - found dead

SD - sacrificed by design

Company Sanitized. Does not contain TSCA CBI

H-24943: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-6544

DEIONIZED WATER (NEGATIVE CONTROL)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

ANIMAL NUMBER	GROUP I								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
646932	197.1	202.1	212.9	221.5	233.6	234.1	242.4	251.1	256.1
646933	191.9	195.4	205.0	213.2	226.5	219.3	232.9	239.5	246.4
646934	182.6	188.9	195.4	207.0	213.9	215.9	224.2	230.9	238.1
646935	203.0	208.9	218.0	228.1	239.7	243.0	257.2	265.7	270.5
646936	196.8	201.4	208.6	204.0	216.7	218.6	229.9	234.9	240.3

TEST DAY

ANIMAL NUMBER	Day 10
646932	264.7 SD test day 10
646933	254.4 SD test day 10
646934	248.6 SD test day 10
646935	278.0 SD test day 10
646936	248.1 SD test day 10

H-24943: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-6544

DEIONIZED WATER (NEGATIVE CONTROL)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP III

ANIMAL NUMBER	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
646937	184.5	186.8	199.0	205.9	213.6	221.0	229.6	238.7	241.4
646938	163.7	173.8	180.9	189.3	200.6	204.1	215.9	221.8	228.3
646939	193.3	204.2	214.6	221.1	234.4	240.7	248.9	259.2	267.3
646940	191.5	197.1	203.8	209.8	218.5	222.1	229.3	232.0	237.5
646941	191.6	195.9	207.9	216.8	223.1	231.2	241.3	249.1	257.0

ANIMAL NUMBER	TEST DAY								
	Day 10	Day 17	Day 24	Day 31	Day 38	Day 45	Day 52	Day 59	Day 67
646937	249.8	282.6	322.3	366.1	395.0	425.0	443.9	461.7	478.7
646938	237.2	270.4	296.5	325.8	342.9	367.5	373.7	378.7	401.3
646939	277.9	329.7	372.8	415.2	443.2	475.2	484.1	505.7	516.4
646940	244.5	271.5	291.3	317.9	332.8	356.3	367.0	380.3	392.5
646941	266.3	312.4	344.8	371.6	390.7	412.8	433.6	455.8	475.3

ANIMAL NUMBER	TEST DAY				
	Day 73	Day 80	Day 87	Day 94	
646937	504.3	520.5	533.7	545.7	SD test day 94
646938	417.4	431.0	432.1	450.6	SD test day 94
646939	540.1	568.9	578.1	586.9	SD test day 94
646940	407.3	424.0	430.8	449.4	SD test day 94
646941	493.7	503.5	513.8	525.8	SD test day 94

H-24943: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-6544

H-24019 (POSITIVE CONTROL)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

ANIMAL NUMBER	GROUP I								
	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
646910	184.3	185.3	197.3	204.8	212.7	216.3	226.4	232.3	237.5
646911	184.4	187.1	195.7	202.0	211.7	217.2	225.2	225.6	231.9
646912	180.5	185.9	195.9	202.5	211.9	217.7	227.2	232.4	238.5
646913	186.4	189.7	198.1	205.7	221.8	225.0	228.6	238.4	245.8
646914	185.5	189.6	198.8	203.8	215.4	222.7	226.7	231.5	238.8

TEST DAY

ANIMAL
NUMBER

Day 10

646910	241.1	SD test day 10
646911	236.6	SD test day 10
646912	241.9	SD test day 10
646913	257.0	SD test day 10
646914	243.0	SD test day 10

H-24943: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-6544

H-24019 (POSITIVE CONTROL)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP III

ANIMAL NUMBER	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
646915	182.7	188.3	200.1	206.3	211.1	220.6	225.8	231.1	236.8
646916	185.0	192.7	205.5	211.6	220.0	226.9	239.5	240.1	249.3
646917	187.8	194.3	205.8	210.4	221.8	227.5	233.9	235.8	244.3
646918	175.5	181.9	189.8	197.6	207.0	212.4	220.2	224.1	228.2
646919	192.0	196.9	207.9	218.9	228.3	234.0	240.8	245.8	252.9

ANIMAL NUMBER	TEST DAY								
	Day 10	Day 17	Day 24	Day 31	Day 38	Day 45	Day 52	Day 59	Day 67
646915	240.4	283.4	302.9	326.7	337.9	371.1	399.7	412.5	433.1
646916	257.0	310.0	334.4	383.2	411.9	450.3	469.8	494.8	511.8
646917	250.2	280.3	308.2	339.7	362.8	387.9	409.0	420.0	441.5
646918	237.1	270.6	292.7	323.2	350.8	379.4	396.7	418.8	433.8
646919	260.2	306.1	328.5	369.2	390.4	427.3	439.0	451.7	457.6

ANIMAL NUMBER	TEST DAY				
	Day 73	Day 80	Day 87	Day 94	
646915	461.2	475.0	498.1	513.3	SD test day 94
646916	544.2	565.5	578.5	590.9	SD test day 94
646917	457.5	464.7	479.5	495.7	SD test day 94
646918	448.1	472.5	480.8	500.3	SD test day 94
646919	489.5	504.8	524.2	522.9	SD test day 94

H-24943: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-6544

H-24020 (POSITIVE CONTROL)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP I

ANIMAL NUMBER	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
646921	204.5	204.9	215.7	222.2	233.3	238.8	244.3	244.9	252.2
646922	178.3	180.9	188.9	197.4	197.7	202.4	202.4	204.0	207.7
646923	185.9	185.1	196.0	202.3	203.5	204.9	219.1	224.9	231.7
646924	188.7	194.6	209.5	212.6	230.4	225.9	236.2	236.5	250.9
646925	172.2	176.0	183.9	193.4	202.7	202.7	215.1	221.5	228.7

TEST DAY

ANIMAL NUMBER	Day 10
646921	262.6 SD test day 10
646922	218.6 SD test day 10
646923	240.6 SD test day 10
646924	259.1 SD test day 10
646925	234.8 SD test day 10

Company Sanitized. Does not contain TSCA CBI

H-24943: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-6544

H-24020 (POSITIVE CONTROL)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP III

ANIMAL NUMBER	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
646926	182.0	187.8	197.0	203.6	206.0	213.2	222.9	229.9	239.7
646927	172.2	178.8	191.1	195.1	206.6	213.2	218.2	228.7	233.1
646928	190.4	195.3	204.5	212.3	222.1	230.1	236.1	235.8	243.4
646929	178.6	182.5	190.7	198.3	203.5	204.2	214.6	210.3	219.2
646930	187.9	191.6	201.0	210.4	219.6	224.4	226.7	232.6	235.3

ANIMAL NUMBER	TEST DAY								
	Day 10	Day 17	Day 24	Day 31	Day 38	Day 45	Day 52	Day 59	Day 67
646926	250.8	297.2	349.3	383.8	412.1	432.1	467.8	493.2	509.5
646927	243.3	306.2	355.1	404.0	424.8	463.2	484.0	511.7	527.2
646928	254.1	310.6	349.4	392.8	422.4	443.5	464.8	492.2	518.6
646929	225.5	280.9	323.2	376.0	396.8	426.4	450.2	463.8	484.2
646930	240.3	292.3	316.2	352.7	368.4	406.8	436.0	454.7	474.2

ANIMAL NUMBER	TEST DAY			
	Day 73	Day 80	Day 87	Day 94
646926	535.3	551.9	564.4	580.6 SD test day 94
646927	551.2	574.5	541.3	602.5 SD test day 94
646928	540.3	557.0	568.3	581.9 SD test day 94
646929	502.6	509.6	526.7	544.0 SD test day 94
646930	498.5	517.6	530.3	543.4 SD test day 94

H-24943: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-6544

H-24943 (TEST SUBSTANCE)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP I

ANIMAL NUMBER	TEST DAY								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9
648927	249.1	252.6	265.4	272.2	277.6	289.1	295.1	304.9	310.3
648928	253.4	254.5	265.6	273.1	282.3	285.1	294.7	302.8	309.7
648929	261.0	262.0	271.0	275.8	284.7	287.7	285.3	301.4	299.5
648930	240.7	246.9	259.8	264.3	276.0	277.4	277.3	260.5	273.4
648931	255.0	258.8	274.2	274.8	287.5	288.3	301.5	303.5	314.2

TEST DAY

ANIMAL
NUMBER

Day 10

648927	316.6	SD test day 10
648928	317.4	SD test day 10
648929	304.3	SD test day 10
648930	275.0	SD test day 10
648931	318.4	SD test day 10

Company Sanitized. Does not contain TSCA CBI

H-24943: Biopersistence Screening
10-Dose Oral Gavage Study in Rats

DuPont-6544

H-24943 (TEST SUBSTANCE)

INDIVIDUAL BODY WEIGHTS (g) OF MALE RATS

GROUP III

ANIMAL NUMBER	TEST DAY									
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9	
648932	246.2	255.3	265.8	271.1	277.3	297.2	293.5	295.8	303.7	
648933	254.7	266.3	270.4	278.5	287.4	295.0	307.8	309.2	318.3	
648934	264.1	269.9	280.1	288.3	299.8	308.5	317.9	323.6	334.9	
648935	259.0	263.1	270.4	281.4	285.9	297.1	309.2	307.2	316.2	
648936	261.7	266.4	273.7	281.2	295.0	305.6	310.9	316.3	320.8	

ANIMAL NUMBER	TEST DAY									
	Day 10	Day 17	Day 24	Day 31	Day 38	Day 45	Day 52	Day 59	Day 66	
648932	311.2	352.8	387.8	410.4	431.4	453.0	477.5	478.6	500.1	
648933	326.6	368.3	391.7	428.1	450.4	472.2	499.7	514.2	536.4	
648934	335.2	378.7	413.7	451.6	479.1	517.0	546.8	555.1	571.3	
648935	325.7	351.1	377.7	402.4	425.0	448.8	481.6	489.8	501.8	
648936	334.9	367.9	389.6	408.8	427.3	456.2	474.1	483.4	495.4	

ANIMAL NUMBER	TEST DAY			
	Day 73	Day 80	Day 87	Day 94
648932	515.0	535.3	556.4	576.9
648933	541.9	563.5	586.7	600.3
648934	563.4	585.8	605.0	609.0
648935	515.7	535.1	555.8	572.9
648936	504.6	514.1	529.4	543.1

APPENDIX B

Individual Clinical Observations

Company Sanitized. Does not contain TSCA CBI

DEIONIZED WATER (NEGATIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP I

Animal	Observation	Days
646932	General observation, No Abnormality Detected	1
	Eye Observations, Exophthalmus, Left	2-9
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Discharge, Eye left, Black	10
	Sacrificed by design	10
646933	General observation, No Abnormality Detected	1-5
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Eye Observations, Dark, Left	6-10
	Discharge, Eye left, Black	6-7
	Swollen Observations, Mouth	10
	Sacrificed by design	10
646934	General observation, No Abnormality Detected	1-5,10
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Discharge, Eye left, Black	6-9
	Sacrificed by design	10

DEIONIZED WATER (NEGATIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP I (Continued)

Animal	Observation	Days
646935	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Sacrificed by design	10
646936	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Sacrificed by design	10

DEIONIZED WATER (NEGATIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III

Animal	Observation	Days
646937	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	24, 52
	Sacrificed by design	94
646938	General observation, No Abnormality Detected	1-10, 17-45
	Eye Observations, Enophthalmus, Right	80-94
	Eye Observations, Exophthalmus, Right	52-73
	Eye Observations, Bled via Orbital for Clin Path, Bilateral	13, 52
	Eye Observations, Bled via Orbital for Clin Path, Right	24
	Eye Observations, Corneal Opacity, Right	80-94
	Discharge, Eye right, Black	59
	Sacrificed by design	94
646939	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	24, 52
	Sacrificed by design	94

DEIONIZED WATER (NEGATIVE CONTROL)
INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III (Continued)		Days
Animal	Observation	
646940	General observation, No Abnormality Detected	1-10, 17-80, 94
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	24, 52
	Discharge, Nose, Black	87
	Sacrificed by design	94
646941	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Bilateral	52
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	24
	Sacrificed by design	94

H-24019 (POSITIVE CONTROL)			
INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS			
Animal	Observation	GROUP I	Days
646910	General observation, No Abnormality Detected		1-10
	Eye Observations, Bled via Orbital for Clin Path, Left		1,5
	Sacrificed by design		10
646911	General observation, No Abnormality Detected		1,10
	Eye Observations, Bled via Orbital for Clin Path, Left		1,5
	Eye Observations, Dark, Left		2-9
	Sacrificed by design		10
646912	General observation, No Abnormality Detected		1-10
	Eye Observations, Bled via Orbital for Clin Path, Left		1
	Eye Observations, Bled via Orbital for Clin Path, Right		5
	Sacrificed by design		10
646913	General observation, No Abnormality Detected		1-10
	Eye Observations, Bled via Orbital for Clin Path, Left		1,5
	Sacrificed by design		10
646914	General observation, No Abnormality Detected		1-10
	Eye Observations, Bled via Orbital for Clin Path, Left		1,5
	Sacrificed by design		10

H-24019 (POSITIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III

Animal	Observation	Days
646915	General observation, No Abnormality Detected	1, 17-38, 73
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24, 52
	Discharge, Eye right, Red	2-10
	Hair Loss, Forelimb, Right	80
	Hair Loss, Forepaw, Right	45-67, 87-94
	Sacrificed by design	94
646916	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Bilateral	24
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Sacrificed by design	94
646917	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Sacrificed by design	94

H-24019 (POSITIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III (Continued)

Animal	Observation	Days
646918	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Sacrificed by design	94
646919	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Sacrificed by design	94

H-24020 (POSITIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP I

Animal	Observation	Days
646921	General observation, No Abnormality Detected	1,5-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1,5
	Eye Observations, Dark, Left	2-4
	Sacrificed by design	10
646922	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1
	Eye Observations, Bled via Orbital for Clin Path, Right	5
	Sacrificed by design	10
646923	General observation, No Abnormality Detected	1,7-10
	Eye Observations, Exophthalmus, Left	4-6
	Eye Observations, Bled via Orbital for Clin Path, Left	1
	Eye Observations, Bled via Orbital for Clin Path, Right	5
	Eye Observations, Dark, Left	2-6
	Sacrificed by design	10

H-24020 (POSITIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP I (Continued)

Animal	Observation	Days
646924	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1
	Eye Observations, Bled via Orbital for Clin Path, Right	5
	Sacrificed by design	10
646925	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	1
	Eye Observations, Bled via Orbital for Clin Path, Right	5
	Sacrificed by design	10

H-24020 (POSITIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III

Animal	Observation	Days
646926	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Bilateral	52
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Sacrificed by design	94
646927	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Bilateral	52
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Sacrificed by design	94
646928	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24, 52
	Sacrificed by design	94

Company Sanitized. Does not contain TSCA CBR

H-24020 (POSITIVE CONTROL)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III (Continued)

Animal	Observation	Days
646929	General observation, No Abnormality Detected	1-10, 17-31
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Hair Loss, Forelimb, Bilateral	52-73
	Hair Loss, Neck, Left	73
	Hair Loss, Neck, Ventral	38-67, 80-94
	Wound, Superficial, Face	59
	Sacrificed by design	94
646930	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13, 24
	Eye Observations, Bled via Orbital for Clin Path, Right	52
	Sacrificed by design	94

H-24943 (TEST SUBSTANCE)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP I

Animal	Observation	Days
648927	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	5
	Eye Observations, Bled via Orbital for Clin Path, Right	1
	Sacrificed by design	10
648928	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	5
	Eye Observations, Bled via Orbital for Clin Path, Right	1
	Sacrificed by design	10
648929	General observation, No Abnormality Detected	1-5, 7-10
	Eye Observations, Bled via Orbital for Clin Path, Left	5
	Eye Observations, Bled via Orbital for Clin Path, Right	1
	Discharge, Eye left, Black	5
	Sacrificed by design	10

Company Sanitized Does not contain TSCA CBM

H-24943 (TEST SUBSTANCE)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP I (Continued)

Animal	Observation	Days
648930	General observation, No Abnormality Detected	1-4, 7-10
	Eye Observations, Bled via Orbital for Clin Path, Left	5
	Eye Observations, Bled via Orbital for Clin Path, Right	1
	Discharge, Nose, Black	5-6
	Sacrificed by design	10
648931	General observation, No Abnormality Detected	1-10
	Eye Observations, Bled via Orbital for Clin Path, Left	5
	Eye Observations, Bled via Orbital for Clin Path, Right	1
	Sacrificed by design	10

H-24943 (TEST SUBSTANCE)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III

Animal	Observation	Days
648932	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	24, 52
	Sacrificed by design	94
648933	General observation, No Abnormality Detected	1-10, 17-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	24, 52
	Sacrificed by design	94
648934	General observation, No Abnormality Detected	1-10, 17-52, 94
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	24, 52
	Eye Observations, Corneal Opacity, Right	59-87
	Sacrificed by design	94

H-24943 (TEST SUBSTANCE)

INDIVIDUAL CLINICAL OBSERVATIONS IN MALE RATS

GROUP III (Continued)

Animal	Observation	Days
648935	General observation, No Abnormality Detected	1-10, 17-24, 66-94
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	24, 52
	Hair Loss, Forepaw, Bilateral	31-59
	Sacrificed by design	94
648936	General observation, No Abnormality Detected	1-10, 17
	Eye Observations, Bled via Orbital for Clin Path, Bilateral	52
	Eye Observations, Bled via Orbital for Clin Path, Left	13
	Eye Observations, Bled via Orbital for Clin Path, Right	24
	Hair Loss, Abdomen, Medial	24-45
	Hair Loss, Abdomen, Right	52-94
	Sacrificed by design	94

APPENDIX C

Terms and Calculations Factors Influencing Interpretation of Kinetic Analysis

Company Sanitized. Does not contain TSCA CBI

TERMS AND CALCULATIONS

Terms:

Active	Fluorine containing compound
% Active	The % of formulation that is made up of fluorine containing components
Mol Wt Active	The molecular weight of the fluorine containing components (g/mole)
Formulation Dose	The mg of formulation given per kg of animal body weight
% F in Active	The % fluorine in the fluorine containing components of the formulation (weight basis)
Mol Wt F	The molecular weight of fluorine g/mol

Compound Calculations:

Dose Active (mg/kg)	The mg of fluorine containing compound administered per kg of animal body weight. $= (\% \text{ active}/100) \times \text{Formulation Dose}$
Dose Active (mmole/kg)	The mmole of fluorine containing compound administered per kg of animal body weight $= \text{dose [mg/kg]} / \text{Mol Wt Active [mg/mmol]}$
Dose F (mg/kg)	The mg Fluorine administered per kg of animal body weight $= (\% \text{ F in active}/100) \times \text{Dose Active [mg/kg]}$
Dose F (mmol/kg)	The mmole of fluorine administered per kg of animal body weight $= \text{Dose F [mg/kg]} / \text{Mol Wt F [mg/mmol]}$
Molar Ratio (Active/F)	The moles of fluorine containing compound per mole of fluorine $= \text{Dose Active [mmol/kg]} / \text{Dose F [mmol/kg]}$
Formulation Dose Normalization Factor	The formulation dose that would be required to administer the amount of active needed to achieve the normalized dose $= (\text{Normalized dose of Active [mmol/kg]} / \text{Dose Active [mmol/kg]}) \times \text{Formulation Dose}$

Company Sanitized. Does not contain TSCA CBI

TERMS AND CALCULATIONS

Individual Animal Measurement:

ppm F The ppm fluoride measured

Individual Animal Calculations:

ppm F minus
Bkg 0.2 ppm The ppm fluoride measured minus the background fluoride measured in control animal. In this case the value was established at 0.2 ppm.

ppm F
normalized to
0.1 mmol/kg Dose The ppm fluoride minus background that would be expected if the active dose was 0.1 mmol/kg instead of the actual active dose. This assumes linearity between administered dose and blood fluorine levels, but is needed because different doses of active were used in the study.

$$= (0.1 \text{ [mmol/kg]} / \text{Active dose [mmol/kg]}) \times (\text{ppm F in blood} \\ \text{minus background})$$

μmolar equivalents of
active The μmolar [μmol/L] concentration of fluorine containing compound based on the ppm fluorine normalized to 0.1 mmol/kg active dose. This assumes that all fluorine is derived from the fluorine-containing component in the formulation. Note: 1 ppm = 1 mg/L

$$= (\text{Normalized ppm [mg/L] fluorine} / \text{Mol Wt F [mg/mmol]}) \times \\ \text{molar ratio active/F [mmol active/mmol F]} \times 1000 \text{ } \mu\text{mol/mmol}$$

Company Sanitized. Does not contain TSCA CBI

FACTORS INFLUENCING INTERPRETATION OF KINETIC ANALYSIS

Considerations:

- The data used for kinetic analysis was from a limited screen and extrapolation should be done cautiously.
- Sample size is low
- Analytical data used without validation
- Steady-state not reached
- Terminal phase may not be reached
- Some compounds are mixtures of fluorinated compounds
- Different active and formulation doses were used
- Different vehicles were used to deliver formulations
- Each compound may have very different potency for producing toxicity

Assumptions: (May or may not be justified in all cases)

- Fluorine concentrations are linear with respect to dose
- Analytical method is appropriate for all types of compounds
- Elimination kinetics can be determined based on total fluorine rather than on concentrations of individual components
- Background Fluorine is 0.2 ppm
- % F data is the % Fluorine of the active (Fluorine containing component(s) in the formulation)
- Molecular weight is the molecular weight of the active component in the formulation

Company Sanitized. Does not contain TSCA CBI

APPENDIX D

Individual Fluorine Levels in Blood

Company Sanitized. Does not contain TSCA CBI

Data for H-24019

Given:

Mol Wt. Active (g/mole):	497	% F in Active:	65
Formulation Dose (mg/kg):	10	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	10	Molar Ratio (Active/F):	0.059
Dose Active (mmole/kg):	0.020	Dose F (mg/kg):	6.5
Dose F (mmol/kg):	0.342		

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group I					
646910	1	2.6	2.4	11.93	36.92
646911	1	2.7	2.5	12.43	38.46
646912	1	2.5	2.3	11.43	35.38
646913	1	2.6	2.4	11.93	36.92
646914	1	2.6	2.4	11.93	36.92
Group I					
646910	5	30.1	29.9	148.60	460.00
646911	5	30.3	30.1	149.60	463.08
646912	5	31.3	31.1	154.57	478.46
646913	5	32.2	32.0	159.04	492.31
646914	5	32.7	32.5	161.53	500.00
Group I					
646910	10	71.5	71.3	354.36	1096.92
646911	10	70.5	70.3	349.39	1081.54
646912	10	66.9	66.7	331.50	1026.15
646913	10	62.5	62.3	309.63	958.46
646914	10	68.6	68.4	339.95	1052.31

Company Sanitized. Does not contain TSCA CBI

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group III					
646915	13	55.0	54.8	272.36	843.08
646916	13	55.3	55.1	273.85	847.69
646917	13	52.2	52.0	258.44	800.00
646918	13	53.8	53.6	266.39	824.62
646919	13	53.6	53.4	265.40	821.54
Group III					
646915	24	38.9	38.7	192.34	595.38
646916	24	43.8	43.6	216.69	670.77
646917	24	37.6	37.4	185.88	575.38
646918	24	35.4	35.2	174.94	541.54
646919	24	42.4	42.2	209.73	649.23
Group III					
646915	52	23.2	23.0	114.31	353.85
646916	52	20.3	20.1	99.90	309.23
646917	52	25.9	25.7	127.73	395.38
646918	52	24.9	24.7	122.76	380.00
646919	52	23.5	23.3	115.80	358.46
Group III					
646915	94	13.3	13.1	65.11	201.54
646916	94	11.7	11.5	57.16	176.92
646917	94	12.9	12.7	63.12	195.38
646918	94	11.0	10.8	53.68	166.15
646919	94	14.1	13.9	69.08	213.85

Company Sanitized. Does not contain TSCA CBI

Data for H-24020

Given:

Mol Wt. Active (g/mole):	426	% F in Active:	69
Formulation Dose (mg/kg):	20	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	20	Molar Ratio (Active/F):	0.065
Dose Active (mmole/kg):	0.047	Dose F (mg/kg):	13.8
Dose F (mmol/kg):	0.726		

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group I					
646921	1	10.6	10.4	22.15	75.36
646922	1	10.7	10.5	22.37	76.09
646923	1	9.2	9.0	19.17	65.22
646924	1	5.3	5.1	10.86	36.96
646925	1	11.2	11.0	23.43	79.71
Group I					
646921	5	78.7	78.5	167.21	568.84
646922	5	83.2	83.0	176.79	601.45
646923	5	77.0	76.8	163.58	556.52
646924	5	66.1	65.9	140.37	477.54
646925	5	69.6	69.4	147.82	502.90
Group I					
646921	10	63.0	62.8	133.76	455.07
646922	10	69.1	68.9	146.76	499.28
646923	10	60.3	60.1	128.01	435.51
646924	10	62.5	62.3	132.70	451.45
646925	10	53.9	53.7	114.38	389.13

Company Sanitized. Does not contain TSCA CBI

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group III					
646926	13	34.8	34.6	73.70	250.72
646927	13	30.0	29.8	63.47	215.94
646928	13	23.7	23.5	50.06	170.29
646929	13	33.7	33.5	71.36	242.75
646930	13	25.4	25.2	53.68	182.61
Group III					
646926	24	11.9	11.7	24.92	84.78
646927	24	10.4	10.2	21.73	73.91
646928	24	8.1	7.9	16.83	57.25
646929	24	15.7	15.5	33.02	112.32
646930	24	9.8	9.6	20.45	69.57
Group III					
646926	52	2.5	2.3	4.90	16.67
646927	52	1.7	1.5	3.20	10.87
646928	52	1.3	1.1	2.34	7.97
646929	52	4.0	3.8	8.09	27.54
646930	52	1.8	1.6	3.41	11.59
Group III					
646926	94	0.8	0.6	1.28	4.35
646927	94	<0.5	*	*	*
646928	94	<0.5	*	*	*
646929	94	0.9	0.7	1.49	5.07
646930	94	<0.5	*	*	*

* Below LOQ (Limit of Quantification)

Company Sanitized. Does not contain TSCA CBI

Data for H-24943

Given:

Mol Wt. Active (g/mole):	150000	% F in Active:	15.5
Formulation Dose (mg/kg):	1000	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	30		

Calculated Values:

Dose Active (mg/kg):	300	Molar Ratio (Active/F):	0
Dose Active (mmole/kg):	0	Dose F (mg/kg):	46.5
Dose F (mmol/kg):	2.4		

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group I					
648927	1	0.9	0.7	35.0	1.5
648928	1	0.9	0.7	35.0	1.5
648929	1	0.9	0.7	35.0	1.5
648930	1	0.7	0.5	25.0	1.1
648931	1	2.2	2.0	100.0	4.3
Group I					
648927	5	2.8	2.6	130.0	5.6
648928	5	2.0	1.8	90.0	3.9
648929	5	2.4	2.2	110.0	4.7
648930	5	1.9	1.7	85.0	3.7
648931	5	1.9	1.7	85.0	3.7
Group I					
648927	10	2.1	1.9	95.0	4.1
648928	10	1.8	1.6	80.0	3.4
648929	10	1.9	1.7	85.0	3.7
648930	10	2.5	2.3	115.0	4.9
648931	10	3.5	3.3	165.0	7.1

Company Sanitized. Does not contain TSCA CBI

Rat Number	Test Day Sample	ppm F in Blood	ppm F in Blood Minus Bkg 0.2 ppm	ppm F in Blood Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Blood
Group III					
648932	13	1.8	1.6	80.0	3.4
648933	13	1.9	1.7	85.0	3.7
648934	13	1.8	1.6	80.0	3.4
648935	13	1.8	1.6	80.0	3.4
648936	13	1.7	1.5	75.0	3.2
Group III					
648932	24	<0.5			
648933	24	<0.5			
648934	24	<0.5			
648935	24	<0.5			
648936	24	<0.5			
Group III					
648932	52	<0.5			
648933	52	0.7	0.5	25.0	1.1
648934	52	<0.5			
648935	52	<0.5			
648936	52	0.6	0.4	20.0	0.9
Group III					
648932	94	<0.5			
648933	94	<0.5			
648934	94	<0.5			
648935	94	<0.5			
648936	94	<0.5			

Company Sanitized. Does not contain TSCA CBI

APPENDIX E

Individual Fluorine Levels in Liver

Company Sanitized. Does not contain TSCA CER

Data for H-24019

Given:

Mol Wt. Active (g/mole):	497	% F in Active:	65
Formulation Dose (mg/kg):	10	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	10	Molar Ratio (Active/F):	0.059
Dose Active (mmole/kg):	0.020	Dose F (mg/kg):	6.5
Dose F (mmol/kg):	0.342		

Rat Number	Test Day Sample	ppm F in Liver	ppm F in Liver Minus Bkg 0.2 ppm	ppm F in Liver Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Liver
Group I					
646910	10	320.9	320.7	1593.88	4933.85
646911	10	334.0	333.8	1658.99	5135.38
646912	10	318.6	318.4	1582.45	4898.46
646913	10	281.6	281.4	1398.56	4329.23
646914	10	306.6	306.4	1522.81	4713.85
Group III					
646915	94	85.6	85.4	424.44	1313.85
646916	94	75.9	75.7	376.23	1164.62
646917	94	87.5	87.3	433.88	1343.08
646918	94	78.0	77.8	386.67	1196.92
646919	94	94.2	94.0	467.18	1446.15

Company Sanitized. Does not contain TSCA CBI

Data for H-24020

Given:

Mol Wt. Active (g/mole):	426	% F in Active:	69
Formulation Dose (mg/kg):	20	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	20	Molar Ratio (Active/F):	0.065
Dose Active (mmole/kg):	0.047	Dose F (mg/kg):	13.8
Dose F (mmol/kg):	0.726		

Rat Number	Test Day Sample	ppm F in Liver	ppm F in Liver Minus Bkg 0.2 ppm	ppm F in Liver Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Liver
Group I					
646921	10	118.3	118.1	251.55	855.80
646922	10	122.7	122.5	260.93	887.68
646923	10	114.3	114.1	243.03	826.81
646924	10	121.6	121.4	258.58	879.71
646925	10	122.1	121.9	259.65	883.33
Group III					
646926	94	1.8	1.6	3.41	11.59
646927	94	1.2	1.0	2.13	7.25
646928	94	2.2	2.0	4.26	14.49
646929	94	4.7	4.5	9.59	32.61
646930	94	2.9	2.7	5.75	19.57

Company Sanitized. Does not contain TSCA CBI

Data for H-24943

Given:

Mol Wt. Active (g/mole):	150000	% F in Active:	15.5
Formulation Dose (mg/kg):	1000	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	30		

Calculated Values:

Dose Active (mg/kg):	300	Molar Ratio (Active/F):	0
Dose Active (mmole/kg):	0	Dose F (mg/kg):	46.5
Dose F (mmol/kg):	2.4		

Rat Number	Test Day Sample	ppm F in Liver	ppm F in Liver Minus Bkg 0.2 ppm	ppm F in Liver Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Liver
Group I					
648927	10	23.5	23.3	1165.0	50.1
648928	10	21.0	20.8	1040.0	44.7
648929	10	21.5	21.3	1065.0	45.8
648930	10	27.4	27.2	1360.0	58.5
648931	10	18.4	18.2	910.0	39.1
Group III					
648932	94	1.5	1.3	65.0	2.8
648933	94	1.8	1.6	80.0	3.4
648934	94	1.3	1.1	55.0	2.4
648935	94	1.6	1.4	70.0	3.0
648936	94	1.6	1.4	70.0	3.0

Company Sanitized. Does not contain TSCA CBI

APPENDIX F

Individual Fluorine Levels in Fat

Company Sanitized. Does not contain TSCA CB

Data for H-24019

Given:

Mol Wt. Active (g/mole):	497	% F in Active:	65
Formulation Dose (mg/kg):	10	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	10	Molar Ratio (Active/F):	0.059
Dose Active (mmole/kg):	0.020	Dose F (mg/kg):	6.5
Dose F (mmol/kg):	0.342		

Rat Number	Test Day Sample	ppm F in Fat	ppm F in Fat Minus Bkg 0.2 ppm	ppm F in Fat Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Fat
Group I					
646910	10	14.4	14.2	70.57	218.46
646911	10	14.9	14.7	73.06	226.15
646912	10	10.9	10.7	53.18	164.62
646913	10	11.6	11.4	56.66	175.38
646914	10	12.4	12.2	60.63	187.69
Group III					
646915	94	1.3	1.1	5.47	16.92
646916	94	1.1	0.9	4.47	13.85
646917	94	1.3	1.1	5.47	16.92
646918	94	0.8	0.6	2.98	9.23
646919	94	1.5	1.3	6.46	20.00

Company Sanitized. Does not contain TSCA CBI

Data for H-24020

Given:

Mol Wt. Active (g/mole):	426	% F in Active:	69
Formulation Dose (mg/kg):	20	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	100		

Calculated Values:

Dose Active (mg/kg):	20	Molar Ratio (Active/F):	0.065
Dose Active (mmole/kg):	0.047	Dose F (mg/kg):	13.8
Dose F (mmol/kg):	0.726		

Rat Number	Test Day Sample	ppm F in Fat	ppm F in Fat Minus Bkg 0.2 ppm	ppm F in Fat Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Fat
Group I					
646921	10	6.2	6.0	12.78	43.48
646922	10	8.5	8.3	17.68	60.14
646923	10	8.7	8.5	18.11	61.59
646924	10	8.8	8.6	18.32	62.32
646925	10	8.3	8.1	17.25	58.70
Group III					
646926	94	ND	ND	ND	ND
646927	94	ND	ND	ND	ND
646928	94	ND	ND	ND	ND
646929	94	ND	ND	ND	ND
646930	94	ND	ND	ND	ND

ND Non-detectable.

Company Sanitized. Does not contain TSCA CBI

Data for H-24943

Given:

Mol Wt. Active (g/mole):	150000	% F in Active:	15.5
Formulation Dose (mg/kg):	1000	Mol Wt. F (g/mol):	19
% Active (F Containing) in Formulation:	30		

Calculated Values:

Dose Active (mg/kg):	300	Molar Ratio (Active/F):	0
Dose Active (mmole/kg):	0	Dose F (mg/kg):	46.5
Dose F (mmol/kg):	2.4		

Rat Number	Test Day Sample	ppm F in Fat	ppm F in Fat Minus Bkg 0.2 ppm	ppm F in Fat Normalized to 0.1 mmoles/kg Dose	μmolar Equivalents of Active in Fat
Group I					
648927	10	16.1	15.9	795.0	34.2
648928	10	18.6	18.4	920.0	39.6
648929	10	27.9	27.7	1385.0	59.6
648930	10	20.1	19.9	995.0	42.8
648931	10	14.3	14.1	705.0	30.3
Group III					
648932	94	2.6	2.4	120.0	5.2
648933	94	3.7	3.5	175.0	7.5
648934	94	3.1	2.9	145.0	6.2
648935	94	2.4	2.2	110.0	4.7
648936	94	4.6	4.4	220.0	9.5

Company Sanitized. Does not contain TSCA CBI